" class="no-js "lang="en-US"> Therorna - Medtech Alert
Saturday, September 20, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Therorna | Pharmtech Focus

Therorna

About Therorna

Therorna

Therorna was founded in April 2021 by Professor Wei Wensheng of Peking University. It mainly studies the research and application of circular RNA technology in the field of innovative drugs and innovative therapies. Not long ago, Wei Wensheng’s research group published a research paper showing that the circular RNA vaccine against the new coronavirus delta variant prepared by the team has broad-spectrum protection against a variety of new coronavirus variants.

Related Story

COVID-19

 Therorna Completes Series A Financing to Accelerate Pipeline Development and Clinical Transformation of circRNA-based Platform | Pharmtech Focus

Therorna Completes Series A Financing to Accelerate Pipeline Development and Clinical Transformation of circRNA-based Platform

June 21 2022

Therorna Inc., a China-based biotech company specialized in the development of cutting-edge circular RNA (or circRNA) […]